We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Stem Cells Derived by Parthenogenesis

By Biotechdaily staff writers
Posted on 21 May 2002
Specialized cell types, including heart and brain cells, have been developed from embryonic monkey stem cells through parthenogenesis by researchers at Advanced Cell Technology (ACT, Worcester, MA, USA) and Wake Forest University School of Medicine (Winston-Salem, NC, USA). More...
The research was reported in the January 31, 2002, issue of Science.

Pathenogenesis is a process by which embryonic development is initiated directly from an unfertilized egg cell, so no fetus develops. The process may avoid the controversy associated with using embryonic stem cells. The researchers generated a pluripotent stem cell line, from which they have produced neurons, heart muscle, smooth muscle, and other kinds of cells. The cell line has grown continuously for 10 months. Potential applications include the treatment of disease where specific cell types have become dysfunctional, such as heart disease, diabetes, and Parkinson's disease. Cells derived from this renewable source might be able to alleviate some technical problems of human cell therapy, say the researchers.

The most remarkable differentiation was the development of midbrain dopamine neurons. "This is a special population of neurons whose efficient generation from primate embryonic stem cells had not been reported previously,” noted Drs. Grant and Vrana, both professors of physiology and pharmacology at Wake Forest.





Related Links:
Univ. of Wake Forest
Advanced Cell Technology

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Automated Clinical Chemistry Analyzer
Envoy 500+
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.